NX210c peptide: A drug candidate to repair the BBB in neurological disorders
Sighild Lemarchant, Chris Greene, Nicolas Rebergue, Gwen Fewell, Damir Janigro, Juliette Le Douce, Sébastien Marie, Yann Godfrin, Annette Janus, Matthew Campbell · FENS Forum 2024
BBB disruption is a disease-driving feature of several neurological disorders, including ALS, yet today no treatment exists to repair the BBB. Here, we screened the effect of a subcommissural organ-spondin-derived peptide (NX210c), known to promote functional recovery in several models of neurological disorders, on BBB integrity.Mouse endothelial cell (EC) monolayers and human BBBs (EC, astrocytes, pericytes) in static or microfluidic conditions, were treated with NX210c (1-100μM) or its vehicle. In mouse EC, NX210c induced a transient increase in occludin levels after 24h treatment (+37%, 100
ePoster · Neuroscience